Drug discovery company iOnctura exercised an exclusive option with Clavius Pharmaceuticals, adding the novel oral TGF-β pathway inhibitor, IOA-359, to its pipeline. The company also received a grant from Health Holland and KWF in collaboration with the University of Twente. iOnctura is solely responsible for global development and commercialization of the small molecule inhibitor.
The funding will be used for the development of IOA-359 and the characterization of resistance mechanisms.
iOnctura is a clinical-stage biotech company focused on developing selective cancer therapies that target critical tumor survival pathways. They are using data-driven precision oncology methods to design combination treatments that overcome resistance pathways. iOnctura has two candidates in mid-stage clinical development, IOA-244 and IOA-289, while IOA-359 is undergoing preclinical preparations. The company is headquartered in Amsterdam, with a subsidiary in Geneva.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.